Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95


Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.


High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate.; Wellcome Trust Case Control Consortium., Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.


Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)..

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.


Oncogenic osteomalacia, raised FGF-23, and renal Fanconi syndrome.

Norden AG, Laing RJ, Rowe P, Unwin RJ, Wrong O, Crisp AJ.

QJM. 2014 Feb;107(2):139-41. doi: 10.1093/qjmed/hcr247. Epub 2011 Dec 16. No abstract available.


Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; Wellcome Trust Case Control Consortium.; British Society for Rheumatology Biologics Register., Barton A.

Arthritis Rheum. 2011 Mar;63(3):645-53. doi: 10.1002/art.30130.


Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate., Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.


Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.

Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS..

Pharmacogenet Genomics. 2009 Apr;19(4):319-23. doi: 10.1097/FPC.0b013e328328d51f.


Hypovitaminosis D among rheumatology outpatients in clinical practice.

Mouyis M, Ostor AJ, Crisp AJ, Ginawi A, Halsall DJ, Shenker N, Poole KE.

Rheumatology (Oxford). 2008 Sep;47(9):1348-51. doi: 10.1093/rheumatology/ken203. Epub 2008 May 22.


Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A; BRAGGSS..

Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ard.2007.084715. Epub 2008 Mar 28. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.


Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.

Ostör AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ, Scott DG.

J Rheumatol. 2006 Mar;33(3):622-8.


Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment.

Lim AY, Ostor AJ, Love S, Crisp AJ.

Ann Rheum Dis. 2005 Jun;64(6):965-6. No abstract available.


Referrals to hospital-based rheumatology and orthopaedic services: seeking direction.

Speed CA, Crisp AJ.

Rheumatology (Oxford). 2005 Apr;44(4):469-71. Epub 2005 Feb 16.


The treatment of Paget's disease.

Crisp AJ.

Rheumatology (Oxford). 2005 Feb;44(2):262-3; author reply 262. Epub 2005 Jan 5. No abstract available.


Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab.

Ostor AJ, Crisp AJ, Somerville MF, Scott DG.

BMJ. 2004 Nov 27;329(7477):1266. No abstract available.


The high prevalence of low bone density in men aged 55 yr and over presenting with low trauma fractures to an accident and emergency department.

Gaber TA, Love S, Crisp AJ.

Rheumatology (Oxford). 2003 Jun;42(6):807-8. No abstract available.


Pamidronate for SAPHO syndrome.

Crisp AJ.

Rheumatology (Oxford). 2003 Mar;42(3):491. No abstract available.


Bone density in chronic low back pain: a pilot study.

Gaber TA, McGlashan KA, Love S, Jenner JR, Crisp AJ.

Clin Rehabil. 2002 Dec;16(8):867-70.


Title of Dr should be sufficient for all doctors.

Crisp AJ.

BMJ. 2001 Mar 10;322(7286):617. No abstract available.


A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients.

Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH.

J Bone Miner Res. 2000 Dec;15(12):2315-29.


Reflex sympathetic dystrophy.

Marshall AT, Crisp AJ.

Rheumatology (Oxford). 2000 Jul;39(7):692-5. No abstract available.


Supplemental Content

Loading ...
Support Center